Vol. 18 No. 2 (2019)
Original Articles

Diabetic pneumopathy: A study of induced sputum and pulmonary function in patients with type 2 diabetes mellitus

Rogério M. Bártholo
Thoracic Disease Department. Medical Sciences Faculty. Rio de Janeiro State University. Rio de Janeiro, Brazil.
Elizabeth Bessa
Thoracic Disease Department. Medical Sciences Faculty. Rio de Janeiro State University. Rio de Janeiro, Brazil.
Thiago P. Bártholo
Thoracic Disease Department. Medical Sciences Faculty. Rio de Janeiro State University. Rio de Janeiro, Brazil.
Cláudia Henrique da Costa
Thoracic Disease Department. Medical Sciences Faculty. Rio de Janeiro State University. Rio de Janeiro, Brazil.
Agnaldo José Lopes
Thoracic Disease Department. Medical Sciences Faculty. Rio de Janeiro State University. Rio de Janeiro, Brazil.
Rogério Rufino
Thoracic Disease Department. Medical Sciences Faculty. Rio de Janeiro State University. Rio de Janeiro, Brazil.

Published 2020-01-03

Keywords

  • Diabetes mellitus type 2,
  • Induced sputum,
  • Lymphocytes

How to Cite

1.
Rogério M. Bártholo, Elizabeth Bessa, Thiago P. Bártholo, Cláudia Henrique da Costa, Agnaldo José Lopes, Rogério Rufino. Diabetic pneumopathy: A study of induced sputum and pulmonary function in patients with type 2 diabetes mellitus. BJHBS [Internet]. 2020 Jan. 3 [cited 2024 Oct. 11];18(2):144-50. Available from: https://bjhbs.hupe.uerj.br/bjhbs/article/view/123

Abstract

Objective: To evaluate the cellularity, and albumin and interleukin (IL)-1 levels in induced sputum (IS), and to determine respiratory function parameters in patients with type 2 diabetes mellitus (DM2). Design: A cross-section study in type 2 diabetes mellitus. Participants: Patients with type 2 diabetes mellitus and healthy people. Methods: Patients in both groups had normal chest x-ray findings. Exclusion criteria for both groups were: the presence of current pulmonary disease or sequelae, smoking, respiratory atopy, or respiratory infection in the past 3 months. The study consisted of two sub-studies. In sub-study 1 (SS1), measurements of pulmonary volume and flow, and diffusion capacity for carbon monoxide (DLCO) were performed. In sub-study 2 (SS2), analysis of cellularity, albumin, and IL-1 in IS was performed. Results: In all, 60 patients (45 women, 75%) with DM2 with a mean age of 59.52 years (SD, 9.03) were included in SS1. The DM2 group included 8 patients with airway obstruction (13.33%) without reversibility with bronchodilators, and 9 with restrictive disease (15.00 %) (p = 0.026). The DLCO was reduced in 17 patients (28.33%) in the DM2 group. In the control group, all individuals had values within the reference intervals. Lymphocytosis was found in the IS of patients with DM2 (p = 0.028). The levels of sputum albumin showed no statistical difference between the two groups. Conclusion: Our findings indicate the presence of pulmonary impairment in DM2, characterized by changes in the respiratory function and a lymphocytosis in IS.

Metrics

Metrics Loading ...

References

  1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545-1602.
  2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033-1046.
  3. OECD (2011), “Diabetes prevalence and incidence”, in Health at a Glance 2011: OECD Indicators, OECD Publishing. http:// dx.doi.org/10.1787/health_glance-2011-13-en. doi: 10.1787/ health_glance-2011-en
  4. Nucci LB, Toscano CM, Maia AL, et al. Brazilian National Campaign for Diabetes Mellitus Detection Working Group. A nationwide population screening program for diabetes in Brazil. Rev Panam Salud Publica. 2004;16:320-327.
  5. Hsia CC, Raskin P. Lung function changes related to diabetes mellitus. Diabetes Technol Ther. 2007;9:S74-82.
  6. Chance WW, Rhee C, Yilmaz C, et al. Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care. 2008;31:1596-601.
  7. Kuziemski K, Specjalski K, Jassem E. Diabetic pulmonary microangiopathy – Fact or Fiction? Pol J Endocrinol. 2011;62:171-175.
  8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:s62- s69.
  9. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS Task Force. Standardization of spirometry. Eur Respir J. 2005;26:319–338.
  10. Neder JA, Andreoni S, Castelo-Filho A, et al. Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res. 1999;32:703–717.
  11. Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1999;47:25-29.
  12. Clavant SP, Sastra SA, Osicka TM, et al. The analysis and characterisation of immuno-unreactive urinary albumin in healthy volunteers. Clin Biochem. 2006;39:143-151.
  13. Enomoto T, Usuki J, Azuma A, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest. 2003;123:2007-11.
  14. Kurth L, Hnizdo E. Change in prevalence of restrictive lung impairment in the U.S. population and associated risk factors: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 2007-2010. Multidiscip Respir Med. 2015;28;10:7.
  15. Bottini P, Scionti L, Santeusanio F, et al. Impairment of the respiratory system in diabetic autonomic neuropathy. Diabetes Nutr Metab. 2000;13:165-172.
  16. Langeron O, Birenbaum A, Le Saché F, et al. Airway management in obese patient. Minerva Anestesiol. 2014;80:382-392.
  17. van der Borst B, Gosker HR, Zeegers MP, et al. Pulmonary function in diabetes. A meta-analysis. Chest. 2010;138:393- 406. doi: 10.1378/chest.09-2622.
  18. Hanson C, Rutten EP, Wouters EF, et al. Influence of diet and obesity on COPD development and outcomes. Int J Chron Obstruct Pulmon Dis. 2014;5;723-733.
  19. Davis WA, Knuiman M, Kendall P, et al; Fremantle Diabetes Study. Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes. Diabetes Care. 2004;27:525-757.
  20. Tsiligianni IG, van der Molen T. A systematic review of the role of vitamin insufficiencies and supplementation in COPD. Respir Res. 2010;6:171.
  21. Hersh CP, Make BJ, Lynch DA, et al. COPDGene and ECLIPSE Investigators. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med. 2014;24;14:164.
  22. Marvisi M, Bartolini L, del Borrello P, et al. Pulmonary function in non-insulin-dependent diabetes mellitus. Respiration. 2001;68: 268-272.
  23. Vracko R, Thorning D, Huang TW. Basal lamina of alveolar epithelial and capillaries. Quantitative changes with aging and diabetes mellitus. Am Rev Respir Dis. 1979;120:973-983.
  24. Agarwal AS, Fuladi AB, Mishra G, et al. Spirometry and diffusion studies in patients with type-2 diabetes mellitus and their association with microvascular complications. Indian J Chest Dis Allied Sci. 2010;52:213-216.
  25. Saler T, Cakmak G, Saglam ZA, et al. The assessment pulmonary diffusing capacity in diabetes mellitus with regard to microalbuminuria. Inter Med. 2009;48:1939-1943.
  26. Klein OL, Jones M, Lee J, et al. Reduced lung diffusion capacity in type 2 diabetes is independent of heart failure. Diabetes Res Clin Pract. 2012;96:e73-75.
  27. Guvener N, Tutuncu NB, Akcay S, et al. Alveolar gas exchange in patients with type 2 diabetes mellitus. Endocr J. 2003;50(6):663-667.
  28. Anandhalakshmi S, Manikandan S, Ganeshkumar P. Alveolar gas exchange and pulmonary functions in patients with type 2 diabetes mellitus. J Clin Diagn Res. 2013; 7:1874-1877.
  29. Meyer KC, Raghu G, Baughman RP, et al. American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004-1014.